Nature Biomedical Engineering: Inhaled nebulized LNP, delivered mRNA vaccine, successfully treated deadly influenza

In 2020, the two mRNA vaccines approved by the FDA for marketing use lipid nanoparticles (LNP) as delivery vehicles, which also makes lipid nanoparticles, a non-viral vector, attract widespread attention

In addition to the systemic administration of this kind of injection, there is also research to atomize the vaccine and deliver it directly to the lungs by inhalation.

Recently, researchers from Emory University School of Medicine in the United States published a research paper titled: Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs in Nature Biomedical Engineering , a sub-Journal of Nature .

This study describes an iterative screening method based on in vivo clustering to identify the chemical characteristics of LNP that improves lung delivery, and constructs a new type of LNP that efficiently delivers RNA to the lungs through aerosolization.

Compound 7C1 is an oligomer-lipid conjugate.

Next, they sprayed the other three groups of LNP with an amount of 43 μg mRNA per mouse

The research team speculates that LNP interactions in the lung can be driven by a variety of forces, including PEG-based hydrophilic interactions and electric charges

Using these three design rules, the research team constructed an LNP named Nebulized Lung Delivery 1 (NLD1) for further analysis

The study described the three principles of LNP design, optimized the composition, molar ratio and structure of LNP composed of lipids, neutral or cationic auxiliary lipids and polyethylene glycol (PEG), and improved the lung delivery of aerosolized LNP It also shows the huge clinical transformation potential of Nebulized Lung Delivery No.

Original source:

Lokugamage, MP, Vanover, D.